1
|
Roubert C, Fontaine E, Upton AM. “Upcycling” known molecules and targets for drug-resistant TB. Front Cell Infect Microbiol 2022; 12:1029044. [PMID: 36275029 PMCID: PMC9582839 DOI: 10.3389/fcimb.2022.1029044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 09/21/2022] [Indexed: 11/13/2022] Open
Abstract
Despite reinvigorated efforts in Tuberculosis (TB) drug discovery over the past 20 years, relatively few new drugs and candidates have emerged with clear utility against drug resistant TB. Over the same period, significant technological advances and learnings around target value have taken place. This has offered opportunities to re-assess the potential for optimization of previously discovered chemical matter against Mycobacterium tuberculosis (M.tb) and for reconsideration of clinically validated targets encumbered by drug resistance. A re-assessment of discarded compounds and programs from the “golden age of antibiotics” has yielded new scaffolds and targets against TB and uncovered classes, for example beta-lactams, with previously unappreciated utility for TB. Leveraging validated classes and targets has also met with success: booster technologies and efforts to thwart efflux have improved the potential of ethionamide and spectinomycin classes. Multiple programs to rescue high value targets while avoiding cross-resistance are making progress. These attempts to make the most of known classes, drugs and targets complement efforts to discover new chemical matter against novel targets, enhancing the chances of success of discovering effective novel regimens against drug-resistant TB.
Collapse
|
2
|
Krome AK, Becker T, Kehraus S, Schiefer A, Gütschow M, Chaverra-Muñoz L, Hüttel S, Jansen R, Stadler M, Ehrens A, Pogorevc D, Müller R, Hübner MP, Hesterkamp T, Pfarr K, Hoerauf A, Wagner KG, König GM. Corallopyronin A: antimicrobial discovery to preclinical development. Nat Prod Rep 2022; 39:1705-1720. [PMID: 35730490 DOI: 10.1039/d2np00012a] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Covering: August 1984 up to January 2022Worldwide, increasing morbidity and mortality due to antibiotic-resistant microbial infections has been observed. Therefore, better prevention and control of infectious diseases, as well as appropriate use of approved antibacterial drugs are crucial. There is also an urgent need for the continuous development and supply of novel antibiotics. Thus, identifying new antibiotics and their further development is once again a priority of natural product research. The antibiotic corallopyronin A was discovered in the 1980s in the culture broth of the Myxobacterium Corallococcus coralloides and serves, in the context of this review, as a show case for the development of a naturally occurring antibiotic compound. The review demonstrates how a hard to obtain, barely water soluble and unstable compound such as corallopyronin A can be developed making use of sophisticated production and formulation approaches. Corallopyronin A is a bacterial DNA-dependent RNA polymerase inhibitor with a new target site and one of the few representatives of this class currently in preclinical development. Efficacy against Gram-positive and Gram-negative pathogens, e.g., Chlamydia trachomatis, Orientia tsutsugamushi, Staphylococcus aureus, and Wolbachia has been demonstrated. Due to its highly effective in vivo depletion of Wolbachia, which are essential endobacteria of most filarial nematode species, and its robust macrofilaricidal efficacy, corallopyronin A was selected as a preclinical candidate for the treatment of human filarial infections. This review highlights the discovery and production optimization approaches for corallopyronin A, as well as, recent preclinical efficacy results demonstrating a robust macrofilaricidal effect of the anti-Wolbachia candidate, and the solid formulation strategy which enhances the stability as well as the bioavailability of corallopyronin A.
Collapse
Affiliation(s)
- Anna K Krome
- Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Germany. .,German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
| | - Tim Becker
- Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Germany. .,German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany
| | - Stefan Kehraus
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Pharmaceutical Biology, University of Bonn, Germany.
| | - Andrea Schiefer
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
| | - Michael Gütschow
- Pharmaceutical & Medicinal Chemistry, University of Bonn, Germany
| | | | - Stephan Hüttel
- Department of Microbial Drugs, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - Rolf Jansen
- Department of Microbial Drugs, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - Marc Stadler
- Department of Microbial Drugs, Helmholtz Centre for Infection Research, Braunschweig, Germany.,German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany
| | - Alexandra Ehrens
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
| | - Domen Pogorevc
- German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany.,Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrucken, Germany
| | - Rolf Müller
- German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany.,Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrucken, Germany
| | - Marc P Hübner
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
| | - Thomas Hesterkamp
- Translational Project Management Office (TPMO), German Center for Infection Research (DZIF), Braunschweig, Germany
| | - Kenneth Pfarr
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
| | - Achim Hoerauf
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
| | - Karl G Wagner
- Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Germany. .,German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany
| | - Gabriele M König
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.,Institute for Pharmaceutical Biology, University of Bonn, Germany.
| |
Collapse
|
3
|
Haupenthal J, Kautz Y, Elgaher WAM, Pätzold L, Röhrig T, Laschke MW, Tschernig T, Hirsch AKH, Molodtsov V, Murakami KS, Hartmann RW, Bischoff M. Evaluation of Bacterial RNA Polymerase Inhibitors in a Staphylococcus aureus-Based Wound Infection Model in SKH1 Mice. ACS Infect Dis 2020; 6:2573-2581. [PMID: 32886885 DOI: 10.1021/acsinfecdis.0c00034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Chronic wounds infected with pathogens such as Staphylococcus aureus represent a worldwide health concern, especially in patients with a compromised immune system. As antimicrobial resistance has become an immense global problem, novel antibiotics are urgently needed. One strategy to overcome this threatening situation is the search for drugs targeting novel binding sites on essential and validated enzymes such as the bacterial RNA polymerase (RNAP). In this work, we describe the establishment of an in vivo wound infection model based on the pathogen S. aureus and hairless Crl:SKH1-Hrhr (SKH1) mice. The model proved to be a valuable preclinical tool to study selected RNAP inhibitors after topical application. While rifampicin showed a reduction in the loss of body weight induced by the bacteria, an acceleration of wound healing kinetics, and a reduced number of colony forming units in the wound, the ureidothiophene-2-carboxylic acid 1 was inactive under in vivo conditions, probably due to strong plasma protein binding. The cocrystal structure of compound 1 with RNAP, that we hereby also present, will be of great value for applying appropriate structural modifications to further optimize the compound, especially in terms of plasma protein binding.
Collapse
Affiliation(s)
- Jörg Haupenthal
- Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)−Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123 Saarbrücken, Saarland, Germany
| | - Yannik Kautz
- Institute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, Saarland, Germany
| | - Walid A. M. Elgaher
- Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)−Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123 Saarbrücken, Saarland, Germany
| | - Linda Pätzold
- Institute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, Saarland, Germany
| | - Teresa Röhrig
- Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)−Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123 Saarbrücken, Saarland, Germany
| | - Matthias W. Laschke
- Institute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Saarland, Germany
| | - Thomas Tschernig
- Institute of Anatomy and Cell Biology, Saarland University, 66421 Homburg, Saarland, Germany
| | - Anna K. H. Hirsch
- Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)−Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123 Saarbrücken, Saarland, Germany
- Department of Pharmacy, Saarland University, Campus Building E8.1, 66123 Saarbrücken, Saarland, Germany
| | - Vadim Molodtsov
- Department of Biochemistry and Molecular Biology, The Center for RNA Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania 16802, United States
| | - Katsuhiko S. Murakami
- Department of Biochemistry and Molecular Biology, The Center for RNA Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania 16802, United States
| | - Rolf W. Hartmann
- Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)−Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123 Saarbrücken, Saarland, Germany
- Department of Pharmacy, Saarland University, Campus Building E8.1, 66123 Saarbrücken, Saarland, Germany
| | - Markus Bischoff
- Institute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, Saarland, Germany
| |
Collapse
|
4
|
Paneth A, Frączek T, Grzegorczyk A, Janowska D, Malm A, Paneth P. A Search for Dual Action HIV-1 Reverse Transcriptase, Bacterial RNA Polymerase Inhibitors. Molecules 2017; 22:E1808. [PMID: 29068373 PMCID: PMC6150362 DOI: 10.3390/molecules22111808] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 10/19/2017] [Accepted: 10/22/2017] [Indexed: 12/03/2022] Open
Abstract
Using molecular modeling approach, potential antibacterial agents with triazole core were proposed. A moderate to weak level of antibacterial activity in most of the compounds have been observed, with best minimal inhibitory concentration (MIC) value of 0.003 mg/mL, as shown by the 15 against S. epidermidis. Studied compounds were also submitted to the antifungal assay. The best antifungal activity was detected for 16 with MIC at 0.125 and 0.25 mg/mL against C. albicans and C. parapsilosis, respectively.
Collapse
Affiliation(s)
- Agata Paneth
- Department of Organic Chemistry, Medical University of Lublin, 20-093 Lublin, Poland.
| | - Tomasz Frączek
- Institute of Applied Radiation Chemistry, Lodz University of Technology, 90-924 Lodz, Poland.
| | - Agnieszka Grzegorczyk
- Department of Pharmaceutical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland.
| | - Dominika Janowska
- Department of Organic Chemistry, Medical University of Lublin, 20-093 Lublin, Poland.
| | - Anna Malm
- Department of Pharmaceutical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland.
| | - Piotr Paneth
- Institute of Applied Radiation Chemistry, Lodz University of Technology, 90-924 Lodz, Poland.
| |
Collapse
|
5
|
Recently disclosed chemical entities as potential candidates for management of tuberculosis. Pharm Pat Anal 2016; 4:317-47. [PMID: 26174569 DOI: 10.4155/ppa.15.13] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Tuberculosis (TB) is one of the deadliest infectious diseases worldwide. The drug discovery process of novel, safe and effective agents to combat TB involves identification of new molecular targets and novel chemical scaffolds. The current anti-TB drug pipeline includes several small molecules with more to follow as new candidates are disclosed. This review highlights the most significant findings described in 78 international, European and US patents for chemically diverse compounds as prospective anti-TB medications. Main points of emphasis include chemical classification, in vitro and in vivo activity, ADME/Tox profile and mycobacterial target as described in each patent. The collective mass of compounds disclosed in the reviewed patents introduces new candidates as potential therapeutic agents for TB infections.
Collapse
|
6
|
Sahner JH, Sucipto H, Wenzel SC, Groh M, Hartmann RW, Müller R. Advanced Mutasynthesis Studies on the Natural α-Pyrone Antibiotic Myxopyronin fromMyxococcus fulvus. Chembiochem 2015; 16:946-53. [DOI: 10.1002/cbic.201402666] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Indexed: 01/27/2023]
|
7
|
Surface plasmon resonance – more than a screening technology: insights in the binding mode of σ70:core RNAP inhibitors. Future Med Chem 2014; 6:1551-65. [DOI: 10.4155/fmc.14.105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: Antibiotic resistance has become a major health problem. The σ70:core interface of bacterial RNA polymerase is a promising drug target. Recently, the coiled-coil and lid-rudder-system of the β’ subunit has been identified as an inhibition hot spot. Materials & methods & Results: By using surface plasmon resonance-based assays, inhibitors of the protein–protein interaction were identified and competition with σ70 was shown. Effective inhibition was verified in an in vitro transcription and a σ70:core assembly assay. For one hit series, we found a correlation between activity and affinity. Mutant interaction studies suggest the inhibitors’ binding site. Conclusion: Surface plasmon resonance is a valuable technology in drug design, that has been used in this study to identify and evaluate σ70:core RNA polymerase inhibitors.
Collapse
|
8
|
Abstract
Covering: up to the end of 2013. Myxobacteria produce a vast range of structurally diverse natural products with prominent biological activities. Here, we provide a detailed description and judge the potential of all antibiotically active myxobacterial compounds as lead structures, pointing out their particularities and, if known, their mode of action. Thus, the review provides an overview of the potential of specific compounds, suitable for future investigations and possible clinical applications.
Collapse
Affiliation(s)
- Till F Schäberle
- Institute for Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.
| | | | | | | |
Collapse
|
9
|
Elgaher WAM, Fruth M, Groh M, Haupenthal J, Hartmann RW. Expanding the scaffold for bacterial RNA polymerase inhibitors: design, synthesis and structure–activity relationships of ureido-heterocyclic-carboxylic acids. RSC Adv 2014. [DOI: 10.1039/c3ra45820b] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
10
|
Sahner JH, Groh M, Negri M, Haupenthal J, Hartmann RW. Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: structure-based optimization of a virtual screening hit. Eur J Med Chem 2013; 65:223-31. [PMID: 23711833 DOI: 10.1016/j.ejmech.2013.04.060] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2013] [Revised: 04/26/2013] [Accepted: 04/27/2013] [Indexed: 11/30/2022]
Abstract
Rising resistance against current antibiotics necessitates the development of antibacterial agents with alternative targets. The "switch region" of RNA polymerase (RNAP), addressed by the myxopyronins, could be such a novel target site. Based on a hit candidate discovered by virtual screening, a small library of 5-phenyl-3-ureidothiophene-2-carboxylic acids was synthesized resulting in compounds with increased RNAP inhibition. Hansch analysis revealed π (lipophilicity constant) and σ (Hammet substituent constant) of the substituents at the 5-phenyl moiety to be crucial for activity. The binding mode was proven by the targeted introduction of a moiety mimicking the enecarbamate side chain of myxopyronin into the hit compound, accompanied by enhanced RNAP inhibitory potency. The new compounds displayed good antibacterial activities against Gram positive bacteria and Gram negative Escherichia coli TolC and a reduced resistance frequency compared to the established antibiotic rifampicin.
Collapse
Affiliation(s)
- J Henning Sahner
- Pharmaceutical and Medicinal Chemistry, Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Department of Drug Design and Optimization, Campus C2 3, 66123 Saarbrücken, Germany
| | | | | | | | | |
Collapse
|
11
|
Hüsecken K, Negri M, Fruth M, Boettcher S, Hartmann RW, Haupenthal J. Peptide-based investigation of the Escherichia coli RNA polymerase σ(70):core interface as target site. ACS Chem Biol 2013; 8:758-66. [PMID: 23330640 DOI: 10.1021/cb3005758] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The number of bacterial strains that are resistant against antibiotics increased dramatically during the past decades. This fact stresses the urgent need for the development of new antibacterial agents with novel modes of action targeting essential enzymes such as RNA polymerase (RNAP). Bacterial RNAP is a large multi-subunit complex consisting of a core enzyme (subunits: α(2)ββ'ω) and a dissociable sigma factor (σ(70); holo enzyme: α(2)ββ'ωσ(70)) that is responsible for promoter recognition and transcription initiation. The interface between core RNAP and σ(70) represents a promising binding site. Nevertheless, detailed studies investigating its druggability are rare. Compounds binding to this region could inhibit this protein-protein interaction and thus holo enzyme formation, resulting in inhibition of transcription initiation. Sixteen peptides covering different regions of the Escherichia coli σ(70):core interface were designed; some of them-all derived from σ(70) 2.2 region-led to a strong RNAP inhibition. Indeed, an ELISA-based experiment confirmed the most active peptide P07 to inhibit the σ(70):core interaction. Furthermore, an abortive transcription assay revealed that P07 impedes transcription initiation. In order to study the mechanism of action of P07 in more detail, molecular dynamics simulations and a rational amino acid replacement study were performed, leading to the conclusion that P07 binds to the coiled-coil region in β' and that its flexible N-terminus inhibits the enzyme by interaction with the β' lid-rudder-system (LRS). This work revisits the β' coiled-coil as a hot spot for the protein-protein interaction inhibition and expands it by introduction of the LRS as target site.
Collapse
Affiliation(s)
- Kristina Hüsecken
- Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Department
of Drug Design and Optimization and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2_3, D-66123
Saarbrücken, Germany
| | - Matthias Negri
- Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Department
of Drug Design and Optimization and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2_3, D-66123
Saarbrücken, Germany
| | - Martina Fruth
- Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Department
of Drug Design and Optimization and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2_3, D-66123
Saarbrücken, Germany
| | - Stefan Boettcher
- Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Department
of Drug Design and Optimization and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2_3, D-66123
Saarbrücken, Germany
| | - Rolf W. Hartmann
- Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Department
of Drug Design and Optimization and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2_3, D-66123
Saarbrücken, Germany
| | - Joerg Haupenthal
- Helmholtz
Institute for Pharmaceutical Research Saarland (HIPS), Department
of Drug Design and Optimization and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2_3, D-66123
Saarbrücken, Germany
| |
Collapse
|
12
|
Wiesler SC, Burrows PC, Buck M. A dual switch controls bacterial enhancer-dependent transcription. Nucleic Acids Res 2012; 40:10878-92. [PMID: 22965125 PMCID: PMC3505966 DOI: 10.1093/nar/gks844] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2012] [Revised: 08/13/2012] [Accepted: 08/13/2012] [Indexed: 12/31/2022] Open
Abstract
Bacterial RNA polymerases (RNAPs) are targets for antibiotics. Myxopyronin binds to the RNAP switch regions to block structural rearrangements needed for formation of open promoter complexes. Bacterial RNAPs containing the major variant σ(54) factor are activated by enhancer-binding proteins (bEBPs) and transcribe genes whose products are needed in pathogenicity and stress responses. We show that (i) enhancer-dependent RNAPs help Escherichia coli to survive in the presence of myxopyronin, (ii) enhancer-dependent RNAPs partially resist inhibition by myxopyronin and (iii) ATP hydrolysis catalysed by bEBPs is obligatory for functional interaction of the RNAP switch regions with the transcription start site. We demonstrate that enhancer-dependent promoters contain two barriers to full DNA opening, allowing tight regulation of transcription initiation. bEBPs engage in a dual switch to (i) allow propagation of nucleated DNA melting from an upstream DNA fork junction and (ii) complete the formation of the transcription bubble and downstream DNA fork junction at the RNA synthesis start site, resulting in switch region-dependent RNAP clamp closure and open promoter complex formation.
Collapse
Affiliation(s)
- Simone C. Wiesler
- Department of Life Sciences, Imperial College London, Sir Alexander Fleming Building, London SW7 2AZ, UK
| | | | - Martin Buck
- Department of Life Sciences, Imperial College London, Sir Alexander Fleming Building, London SW7 2AZ, UK
| |
Collapse
|
13
|
Affiliation(s)
- Wufeng Tang
- Helmholtz Centre for Infection Research, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| | - Evgeny V. Prusov
- Helmholtz Centre for Infection Research, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| |
Collapse
|
14
|
Recent advances in antitubercular natural products. Eur J Med Chem 2012; 49:1-23. [DOI: 10.1016/j.ejmech.2011.12.029] [Citation(s) in RCA: 141] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2011] [Revised: 12/09/2011] [Accepted: 12/20/2011] [Indexed: 11/18/2022]
|
15
|
Glaus F, Altmann KH. Total Synthesis of the Bacterial RNA Polymerase Inhibitor Ripostatin B. Angew Chem Int Ed Engl 2012; 51:3405-9. [DOI: 10.1002/anie.201200871] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2012] [Indexed: 12/13/2022]
|
16
|
Glaus F, Altmann KH. Total Synthesis of the Bacterial RNA Polymerase Inhibitor Ripostatin B. Angew Chem Int Ed Engl 2012. [DOI: 10.1002/ange.201200871] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
17
|
Winter P, Hiller W, Christmann M. Access to Skipped Polyene Macrolides through Ring-Closing Metathesis: Total Synthesis of the RNA Polymerase Inhibitor Ripostatin B. Angew Chem Int Ed Engl 2012; 51:3396-400. [DOI: 10.1002/anie.201108692] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2011] [Indexed: 11/05/2022]
|
18
|
Winter P, Hiller W, Christmann M. Access to Skipped Polyene Macrolides through Ring-Closing Metathesis: Total Synthesis of the RNA Polymerase Inhibitor Ripostatin B. Angew Chem Int Ed Engl 2012. [DOI: 10.1002/ange.201108692] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
19
|
Srivastava A, Talaue M, Liu S, Degen D, Ebright RY, Sineva E, Chakraborty A, Druzhinin SY, Chatterjee S, Mukhopadhyay J, Ebright YW, Zozula A, Shen J, Sengupta S, Niedfeldt RR, Xin C, Kaneko T, Irschik H, Jansen R, Donadio S, Connell N, Ebright RH. New target for inhibition of bacterial RNA polymerase: 'switch region'. Curr Opin Microbiol 2011; 14:532-43. [PMID: 21862392 PMCID: PMC3196380 DOI: 10.1016/j.mib.2011.07.030] [Citation(s) in RCA: 116] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2011] [Revised: 07/28/2011] [Accepted: 07/28/2011] [Indexed: 01/08/2023]
Abstract
A new drug target - the 'switch region' - has been identified within bacterial RNA polymerase (RNAP), the enzyme that mediates bacterial RNA synthesis. The new target serves as the binding site for compounds that inhibit bacterial RNA synthesis and kill bacteria. Since the new target is present in most bacterial species, compounds that bind to the new target are active against a broad spectrum of bacterial species. Since the new target is different from targets of other antibacterial agents, compounds that bind to the new target are not cross-resistant with other antibacterial agents. Four antibiotics that function through the new target have been identified: myxopyronin, corallopyronin, ripostatin, and lipiarmycin. This review summarizes the switch region, switch-region inhibitors, and implications for antibacterial drug discovery.
Collapse
Affiliation(s)
- Aashish Srivastava
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Meliza Talaue
- Center for Biodefense, University of Medicine and Dentistry of New Jersey, Newark NJ 07101, USA
| | - Shuang Liu
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - David Degen
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Richard Y. Ebright
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Elena Sineva
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Anirban Chakraborty
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Sergey Y. Druzhinin
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Sujoy Chatterjee
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Jayanta Mukhopadhyay
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Yon W. Ebright
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Alex Zozula
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Juan Shen
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Sonali Sengupta
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Rui Rong Niedfeldt
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| | - Cai Xin
- College of Chemical Engineering, Sichuan University, Sichuan, Chengdu 610065, PRC
| | - Takushi Kaneko
- Global Alliance for TB Drug Development, New York NY 10004, USA
| | - Herbert Irschik
- Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
| | - Rolf Jansen
- Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
| | - Stefano Donadio
- NAICONS--New Anti-Infectives Consortium, 20138 Milano, Italy
| | - Nancy Connell
- Center for Biodefense, University of Medicine and Dentistry of New Jersey, Newark NJ 07101, USA
| | - Richard H. Ebright
- Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway NJ 08854, USA
| |
Collapse
|
20
|
Winter P, Vaxelaire C, Heinz C, Christmann M. Transforming terpene feedstock into polyketide architecture. Chem Commun (Camb) 2011; 47:394-6. [DOI: 10.1039/c0cc02332a] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
21
|
Li P, Li J, Arikan F, Ahlbrecht W, Dieckmann M, Menche D. Stereoselective Total Synthesis of Etnangien and Etnangien Methyl Ester. J Org Chem 2010; 75:2429-44. [DOI: 10.1021/jo100201f] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Pengfei Li
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Jun Li
- Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstrasse 7, D-38124 Braunschweig, Germany
| | - Fatih Arikan
- Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstrasse 7, D-38124 Braunschweig, Germany
| | - Wiebke Ahlbrecht
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Michael Dieckmann
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
| | - Dirk Menche
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany
- Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstrasse 7, D-38124 Braunschweig, Germany
| |
Collapse
|
22
|
Menche D, Li P, Irschik H. Design, synthesis and biological evaluation of simplified analogues of the RNA polymerase inhibitor etnangien. Bioorg Med Chem Lett 2010; 20:939-41. [DOI: 10.1016/j.bmcl.2009.12.066] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2009] [Revised: 12/15/2009] [Accepted: 12/15/2009] [Indexed: 11/16/2022]
|
23
|
Weissman KJ, Müller R. Myxobacterial secondary metabolites: bioactivities and modes-of-action. Nat Prod Rep 2010; 27:1276-95. [DOI: 10.1039/c001260m] [Citation(s) in RCA: 225] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
24
|
Li P, Li J, Arikan F, Ahlbrecht W, Dieckmann M, Menche D. Total Synthesis of Etnangien. J Am Chem Soc 2009; 131:11678-9. [DOI: 10.1021/ja9056163] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Pengfei Li
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany, and Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| | - Jun Li
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany, and Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| | - Fatih Arikan
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany, and Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| | - Wiebke Ahlbrecht
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany, and Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| | - Michael Dieckmann
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany, and Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| | - Dirk Menche
- Institut für Organische Chemie, Ruprecht-Karls-Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany, and Helmholtz-Zentrum für Infektionsforschung, Medizinische Chemie, Inhoffenstr. 7, D-38124 Braunschweig, Germany
| |
Collapse
|